As­traZeneca or­dered back in­to the penal­ty box on ZS-9 af­ter an­oth­er re­jec­tion on man­u­fac­tur­ing mal­func­tion

This one will re­al­ly hurt at As­traZeneca.

Ten months af­ter the phar­ma gi­ant was side­lined on ZS-9 by man­u­fac­tur­ing is­sues, the team at As­traZeneca is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.